Skip to main content

Advertisement

Table 1 Patient Characteristics

From: Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy

Characteristics (N=62)   n (%)
Age (years)   
 Median (range) 66 (37–93)  
Sex   
 Female   32 (52)
 Male   30 (48)
Karnowsky PS   
 Median (range) 40 (20–80)  
 ≤ 40   32 (52)
 ≥ 50   30 (48)
Site*   
 Bladder   10 (16)
 Lung (NSCLC)   9 (15)
 Endometrial   8 (13)
 Prostate   6 (10)
 Cervical   6 (10)
 Gastric   6 (10)
 Ovarial   6 (10)
 Colorectal   3 (5)
 Others#   8 (13)
Histology+   
 Adenocarcinoma   38 (65)
 Squamous cell carcinoma   6 (10)
 Transitional cell carcinoma   9 (15)
 Others   6 (10)
Tumor-classification+   
 T0   2 (3)
 T3   2 (3)
 T4   55 (94)
Metastasis+   
 No   1 (2)
 Yes   52 (88)
 Unknown   6 (10)
Liver metastasis+   
 No   43 (73)
 Yes   16 (27)
Bleeding Site+   
 Primary tumor   48 (81)
 Metastasis   11 (19)
Symptom   
 Vaginal bleeding   19 (31)
 Hematuria   17 (27)
 Hemoptysis   10 (16)
 Others   16 (26)
First diagnosis to hRT (months)   
 Median (range) 11 (0.3-183)  
  1. Abbreviations: PS=performance status; NSCLC=non-small cell lung cancer; hRT=hemostatic radiotherapy; *Site of the primary tumor; # including esophageal (n=2), sarcoma (n=1), multiple myeloma (n=1), kidney cancer (n=1), non-hodgkin lymphoma (n=1), breast cancer (n=1) and pseudomyxoma peritonei (n=1); +Three patients were not applicable having stage IV non-hodgkin lymphoma according to Ann Arbor (n=1) or stage III multiple myeloma according to Durie and Salmon (n=1) or benign pseudomyxoma peritonei (n=59).